Indeed, PARP inhibitors are widely used in the management of ovarian [87,88] and breast [89,90] cancers with BRCA1/2 mutations, but also in metastatic pancreatic cancer with BRCA1/2 mutations [91]. This evidence concerns the gene BRCA1 and cancer.